Modulation of the inflammatory response benefits treatment-resistant bipolar depression: A randomized clinical trial
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE The goal of this study was to reduce treatment resistance and enhance antidepressant response in patients with treatment-resistant bipolar depression (TRBDD) by modulating inflammatory activation. METHODS Forty-seven TRBDD patients completed a randomized, double-blind, placebo (PBO)-controlled two-arm study using celecoxib (CBX), a cyclooxygenase 2 (COX-2) inhibitor, in combination with escitalopram (ESC). The Hamilton Depression (17-Item) and the Hamilton Anxiety Rating Scales were used to quantify symptom severity. Self-rating instruments included BDI, BAI and QLES-Q questioner. An adverse events inventory was used, and the possibility of bleeding diathesis was monitored. Complete blood count (CBC), prothrombin time (PT), and activated partial thromboplastin time (APTT) were determined. Comparison of mood scores between the CBX and PBO groups were conducted using a mixed ANOVA and an Independent Sample Student t-test. RESULTS The CBX adjunctive treatment produced significantly more responders and remitters than the PBO arm. Compared to the PBO group (n = 20), the CBX group (n = 27) experienced lower depression severity through the entire course of the study, showing significant decrease in depression and anxiety scores as early as week 1. Except for initial mild nausea, no adverse events were reported and study medications were well tolerated. CONCLUSIONS Modulation of the inflammatory response through targeted inhibition of the enzyme COX-2 by means of CBX reduces TRBDD and augments and accelerates treatment response in an efficacious and safe manner. Future studies should replicate these findings and additionally investigate whether prolonged administration of CBX is required to maintain remission by adding a discontinuation phase to the study design. TRIAL REGISTRATION Clinicaltrials.gov ID: NCT01479829.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder 1
Kupka, R. W., Altshuler, L. L., Nolen, W. A., Suppes, T., Luckenbaugh, D. A., Leverich, G. S., Frye, M. A., Keck, P. E., McElroy, S. L., Grunze, H., et al. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00467.x · Cited by 397
Nery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta‐Soares, G. B., Frey, B. N., Bowden, C. L., & Soares, J. C. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.912 · Cited by 298
Cytokine profiles in bipolar affective disorder: focus on acutely ill patients.
O'Brien, S. M., Scully, P., Scott, L. V., & Dinan, T. G. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.11.015 · Cited by 285
Rosenblat, J., & McIntyre, R. (2017) · Brain Sciences · doi:10.3390/brainsci7110144 · Cited by 258
Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., & Brunello, N. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200607000-00005 · Cited by 229
Revisiting inflammation in bipolar disorder
Fries, G. R., Walss-Bass, C., Bauer, M. E., & Teixeira, A. L. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.12.006 · Cited by 147
Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis
Husain, M. I., Strawbridge, R., Stokes, P. R., & Young, A. H. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725711 · Cited by 139
Siwek, M., Sowa-Kućma, M., Styczeń, K., Misztak, P., Nowak, R. J., Szewczyk, B., Dudek, D., Rybakowski, J. K., Nowak, G., & Maes, M. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0124-8 · Cited by 65
Saroukhani, S., Emami‐Parsa, M., Modabbernia, A., Ashrafi, M., Farokhnia, M., Hajiaghaee, R., & Akhondzadeh, S. (2013) · Bipolar Disorders · doi:10.1111/bdi.12108 · Cited by 59
Cited by
Anti-inflammatory medications for the treatment of mental disorders: A scoping review
Fitton, R., Sweetman, J., Heseltine-Carp, W., & van der Feltz-Cornelis, C. (2022) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2022.100518 · Cited by 53
A comparison of inflammatory markers in manic and euthymic states of bipolar disorder
Özdin, S., & Usta, M. B. (2021) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2020.1807048 · Cited by 30
Teixeira, A. L., Martins, L. B., Berk, M., & Bauer, M. E. (2022) · Clinical Science · doi:10.1042/cs20211106 · Cited by 22
Elnazer, H. Y., Sampson, A. P., & Baldwin, D. S. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000356 · Cited by 21
Rapoport, S. I., & Hibbeln, J. R. (2020) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102118 · Cited by 11
Metadata
- Authors
- Halaris, A., Cantos, A., Johnson, K., Hakimi, M., & Sinacore, J.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 261
- Pages
- 145-152
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W2979350907
- Cited by
- 56
- References
- 12
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.